It doesn't always feel like it, but make no mistake, this is what winning looks like

Australian company Telix Pharmaceuticals has opened a major facility in North Melbourne that brings radiochemistry laboratories, clinical product manufacturing, patient dose administration and imaging together under one roof.

"This work is also personally significant. My family has been directly impacted by prostate cancer — my father lives with the disease, and the future risk to my three sons is very real," said new board member Allison Rossiter.

We can pay for private insurance to ensure choice and timely access to a hospital surgery, but not prescription medicines. How does that make sense, and how is it equitable when the only alternative is paying the entire cost?

Organon and Samsung Bioepis have extended their existing collaboration, under which Organon will commercialise a new biosimilar in Australia.

"We are entering one of the most exciting periods in Australian arthritis research that we have ever seen," said Arthritis Australia CEO Louise Hardy.

As the Australian Government approaches negotiations with Medicines Australia and the Generic and Biosimilar Medicines Association for new agreements, the organisation says it is not acceptable to exclude patients, as it has in the past.

The minister's reference to the US and broader international pressures belies the reality that the situation currently confronting MS patients relates to the demanded price reduction triggered by Australia's domestic policies.

The Parliamentary Budget Office’s 2026–27 Medium‑Term Budget Outlook paints a cautious picture for health, disability and medicines spending, with doubts over the budgeted savings for the National Disability Insurance Scheme.

“This isn't simply a cancer story. It's an equity story,” said Meredith Cummins, CEO of NeuroEndocrine Cancer Australia. “Where you live, how far you are from specialist care, and your socioeconomic circumstances are increasingly influencing outcomes for people diagnosed with neuroendocrine cancer.”

Thirteen representatives from government, industry, clinical care, research and patient advocacy met to identify practical actions to strengthen Australia’s paediatric oncology clinical trial ecosystem and attract greater investment so children and young people can access innovative therapies.

Sydney-based Viral Vector Manufacturing Facility and Melbourne-headquartered Mirugen have signed a non-exclusive Letter of Intent to evaluate and potentially develop the company's AAV-based gene therapy candidate targeting Retinitis Pigmentosa.

A trip through a US supermarket or large retail outlet often takes you past a bank, an optometrist, a pharmacy, and sometimes insurance counters. These shops in the US are generally larger and configured to offer these multiple services. Australian supermarkets are typically smaller, and recent retail trends indicate they are shrinking further as retailers optimise floor plans for high‑margin groceries. Simply slotting a pharmacy into that footprint is neither straightforward nor, in most cases, practical. 

The Pharmacy Guild of Australia has rejected the latest report from the Grattan Institute, arguing the analysis misunderstands the role of community pharmacies and risks undermining equitable access to medicines and primary care.

While Australia is debating whether to fund weight-loss medication for a group of very sick people, one American thought leader argues against rationing innovations that are having a profoundly positive impact on quality of life.

This report is an out-of-touch, selectively sourced exercise in policy obsession, with Europe of all places, that ignores the one place where pharmacy supermarkets are common and the overwhelming success of a critical piece of Australia's public health infrastructure.

Another stage in the Delphi studies is the latest equivalent of a menu in a Soviet-era restaurant. This is your choice. Permitted responses are limited to 'yes or no'. No other options will be considered. After almost 1,800 days, we are playing word games over technical inputs that were identified as issues before the review was announced.

Mesoblast Chief Executive Dr Silviu Itescu said, “We are very pleased with the strong uptake of Ryoncil since launch, and with revenues that have already exceeded our initial projections.”

If there’s one thing to say about the PBS, it’s that public debate around the program has long been stagnant. Narrowly focused on process and technical inputs for too long. It has been the policy equivalent of a stagnant body of water.

The MS medicines controversy continues. Why wouldn’t the minister just deal with it and make it go away? It may not be that easy. Why any resolution will probably deal with symptoms rather than the cause. The realities of ministerial offices and the challenges they face that are not visible to outsiders. Another 'phrase of the week' is dissected to reveal its true meaning.